RT Journal Article
SR Electronic
T1 High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.02.20030346
DO 10.1101/2020.03.02.20030346
A1 Keam, Simon P
A1 Halse, Heloise
A1 Nguyen, Thu
A1 Wang, Minyu
A1 Van Kooten Losio, Nicolas
A1 Mitchell, Catherine
A1 Caramia, Franco
A1 Byrne, David J
A1 Haupt, Sue
A1 Ryland, Georgina
A1 Darcy, Phillip K
A1 Sandhu, Shahneen
A1 Blombery, Piers
A1 Haupt, Ygal
A1 Williams, Scott G
A1 Neeson, Paul J
YR 2020
UL http://medrxiv.org/content/early/2020/03/06/2020.03.02.20030346.abstract
AB Prostate cancer (PCa) has a profoundly immunosuppressive microenvironment, we hypothesized that radiation therapy would break this immune suppression. To investigate this, we performed high-throughput immune cell subset analysis, and gene expression profiling of pre-versus post-radiation tissue in a cohort of patients with localized disease that received high dose-rate brachytherapy (HDRBT). We resolved tumor and non-tumor zones in our spatial analysis to explore what drives the immunological response. Nanostring immune profiling revealed numerous immune checkpoint molecules were stimulated in response to HDRBT (e.g. B7-H3, CTLA4, PDL1 and PDL2). A published 16-gene tumor inflammation signature (TIS) gene profiling of immune activation states (high:hot, intermediate and low:cold) showed that most tissues possessed a low TIS pre-HDRBT. Crucially, HDRBT converted 80% of these ‘cold’-phenotype tumors into an ‘intermediate’ or ‘hot’ class. We used digital spatial profiling to show these HDRBT-induced changes in prostate TIS scores were derived from the non-tumor regions. Furthermore, these changes in TIS were also associated with pervasive changes in immune cell density and spatial relationships – in particularly between T cell subsets and antigen presenting cells. We identified increased density of CD4+ FOXP3+ T cells, CD68+ macrophages and CD68+ CD11c+ dendritic cells in response to HDRBT. The only subset change in tumor zones was PDL1+ macrophages. While these immune responses were heterogeneous, HDRBT induced significant changes in immune cell associations, including a gained T cell and HMWCK+ PDL1+ interaction in tumor zones. In conclusion, we showed HDRBT has a clear impact in converting “cold” prostate tumors into more immunologically activated “hot” tissues, with accompanying spatially-organized immune infiltrates and signaling changes. Understanding and potentially harnessing these changes will have widespread implications for the future treatment of localized PCa and the possible use of combination immunotherapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the PeterMac Foundation, the Victorian Cancer Agency, a Prostate Cancer Foundation USA (Creativity award), Cancer Council Victoria (Grant-In-Aid) and an NHMRC Program Grant.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable requestPCaProstate cancerHDRBTHigh dose-rate brachytherapyTISTumor inflammation signatureEBRTExternal beam radiation therapyRTRadiation therapyIHCImmunohistochemistrymIHCMultiplexed immunohistochemistryICImmune checkpointADTAndrogen deprivation therapyPMCCPeter MacCallum Cancer CentreMRIMagnetic resonance imagingPETPositron emission tomographyISUPInternational Society of Urological PathologyFFPEFormalin-fixed paraffin-embeddedGGGleason gradeHIERHeat-induced epitope retrievalDSPDigital spatial profilingROIRegion of interestRBRadBankGEPGene expression profileIOImmuno OncologyAPCAntigen presenting cell